NI202000032A - Compuesto de pirimidina como inhibidor de las janocinasas - Google Patents
Compuesto de pirimidina como inhibidor de las janocinasasInfo
- Publication number
- NI202000032A NI202000032A NI202000032A NI202000032A NI202000032A NI 202000032 A NI202000032 A NI 202000032A NI 202000032 A NI202000032 A NI 202000032A NI 202000032 A NI202000032 A NI 202000032A NI 202000032 A NI202000032 A NI 202000032A
- Authority
- NI
- Nicaragua
- Prior art keywords
- compound
- inhibitor
- janocinases
- pyrimidine compound
- diseases
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- -1 PYRIMIDINE COMPOUND Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 201000004624 Dermatitis Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Dental Preparations (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Abstract
La invención proporciona un compuesto de la fórmula (I): o una sal farmacéuticamente aceptable de este, que es un inhibidor de las janocinasas(JAK). La invención también proporciona composiciones farmacéuticas que comprenden dicho compuesto, una forma cristalina, métodos de uso de dicho compuesto para tratar enfermedades inflamatorias de la piel y otras enfermedades, y procesos y productos intermedios útiles para preparar dicho compuesto.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762577852P | 2017-10-27 | 2017-10-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NI202000032A true NI202000032A (es) | 2020-10-09 |
Family
ID=64277858
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NI202000032A NI202000032A (es) | 2017-10-27 | 2020-04-24 | Compuesto de pirimidina como inhibidor de las janocinasas |
Country Status (37)
| Country | Link |
|---|---|
| US (7) | US10308646B2 (es) |
| EP (1) | EP3672965B1 (es) |
| JP (1) | JP7218364B2 (es) |
| KR (1) | KR102613503B1 (es) |
| CN (1) | CN111247142B (es) |
| AR (1) | AR113803A1 (es) |
| AU (1) | AU2018354370B2 (es) |
| BR (1) | BR112020008015A2 (es) |
| CA (1) | CA3074034A1 (es) |
| CL (1) | CL2020001090A1 (es) |
| CR (1) | CR20200180A (es) |
| CU (1) | CU24671B1 (es) |
| DK (1) | DK3672965T3 (es) |
| DO (1) | DOP2020000083A (es) |
| EA (1) | EA202091016A1 (es) |
| EC (1) | ECSP20023795A (es) |
| ES (1) | ES2932526T3 (es) |
| GE (1) | GEP20227344B (es) |
| HR (1) | HRP20221221T1 (es) |
| HU (1) | HUE060401T2 (es) |
| IL (1) | IL274037B2 (es) |
| LT (1) | LT3672965T (es) |
| MA (1) | MA49956B1 (es) |
| MD (1) | MD3672965T2 (es) |
| MX (1) | MX2020004255A (es) |
| NI (1) | NI202000032A (es) |
| PE (1) | PE20201495A1 (es) |
| PH (1) | PH12020500528A1 (es) |
| PL (1) | PL3672965T3 (es) |
| PT (1) | PT3672965T (es) |
| RS (1) | RS63608B1 (es) |
| SG (1) | SG11202001706RA (es) |
| SI (1) | SI3672965T1 (es) |
| TW (1) | TWI789446B (es) |
| UA (1) | UA125130C2 (es) |
| WO (1) | WO2019084383A1 (es) |
| ZA (1) | ZA202001641B (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GEP20227344B (en) * | 2017-10-27 | 2022-01-25 | Theravance Biopharma R&D Ip Llc | Pyrimidine compound as jak kinase inhibitor |
| EP3889152A4 (en) * | 2018-11-30 | 2022-09-07 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | HETEROAROMATIC DERIVATIVES FOR USE AS REGULATORS, PROCESS FOR THEIR PREPARATION AND THEIR USE |
| US11155549B2 (en) | 2019-04-24 | 2021-10-26 | Theravance Biopharma R&D Ip, Llc | Ester and carbonate pyrimidine compounds as JAK kinase inhibitors |
| CA3135388A1 (en) | 2019-04-24 | 2020-10-29 | Theravance Biopharma R&D Ip, Llc | Pyrimidine jak inhibitors for the treatment of skin diseases |
| KR20230054682A (ko) | 2020-07-28 | 2023-04-25 | 아큐티스 바이오테라퓨틱스, 인크. | Jak 저해제 및 라우레스-4를 함유하는 국소 제형 |
| MX2023002378A (es) * | 2020-08-26 | 2023-05-22 | Nalo Therapeutics | Moduladores de proteinas de la familia de protooncogenes myc. |
| US20230374124A1 (en) * | 2020-10-08 | 2023-11-23 | Icahn School Of Medicine At Mount Sinai | Compositions for treatment alopecia areata, biomarkers for treatment success and, methods of use thereof |
| WO2023076161A1 (en) | 2021-10-25 | 2023-05-04 | Kymera Therapeutics, Inc. | Tyk2 degraders and uses thereof |
| CN114246938A (zh) * | 2022-01-25 | 2022-03-29 | 中山大学中山眼科中心 | Il-4在制备用于治疗视网膜变性疾病药物中的应用 |
| CN115487301B (zh) * | 2022-11-08 | 2023-07-07 | 四川大学华西医院 | Il-13抑制剂在制备延缓或治疗视网膜色素变性的药物中的用途 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4919934A (en) | 1989-03-02 | 1990-04-24 | Richardson-Vicks Inc. | Cosmetic sticks |
| US6660731B2 (en) | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| EP1318997B1 (en) | 2000-09-15 | 2006-05-31 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US6653300B2 (en) | 2000-12-21 | 2003-11-25 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| WO2006067614A2 (en) | 2004-12-23 | 2006-06-29 | Pfizer Products Inc. | Heteroaromatic derivatives useful as anticancer agents |
| CN101360740A (zh) | 2005-11-16 | 2009-02-04 | 沃泰克斯药物股份有限公司 | 可用作激酶抑制剂的氨基嘧啶 |
| EP2044063A1 (en) | 2006-06-30 | 2009-04-08 | Astra Zeneca AB | Pyrimidine derivatives useful in the treatment of cancer |
| US8222256B2 (en) | 2006-07-05 | 2012-07-17 | Exelixis, Inc. | Methods of using IGFIR and ABL kinase modulators |
| CN104011050A (zh) | 2011-12-22 | 2014-08-27 | 霍夫曼-拉罗奇有限公司 | 作为丝氨酸/苏氨酸激酶抑制剂的2,4-二氨基-嘧啶衍生物 |
| WO2015094803A1 (en) * | 2013-12-16 | 2015-06-25 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
| NO2721710T3 (es) * | 2014-08-21 | 2018-03-31 | ||
| JP2017535520A (ja) | 2014-09-30 | 2017-11-30 | ハンミ・ファイン・ケミカル・カンパニー・リミテッドＨａｎｍｉ Ｆｉｎｅ Ｃｈｅｍｉｃａｌ Ｃｏ．， Ｌｔｄ． | 高純度の（ｒ）−９−［２−（ホスホノメトキシ）プロピル］アデニンの製造方法 |
| CA2983453A1 (en) | 2015-05-28 | 2016-12-01 | Theravance Biopharma R&D Ip, Llc | Naphthyridine compounds as jak kinase inhibitors |
| EP3347097B1 (en) | 2015-09-11 | 2021-02-24 | Sunshine Lake Pharma Co., Ltd. | Substituted aminopyrimidine derivatives as modulators of the kinases jak, flt3 and aurora |
| EA035226B1 (ru) | 2016-04-28 | 2020-05-19 | ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи | Пиримидиновые соединения в качестве ингибиторов jak киназы |
| GEP20227344B (en) * | 2017-10-27 | 2022-01-25 | Theravance Biopharma R&D Ip Llc | Pyrimidine compound as jak kinase inhibitor |
| US11155549B2 (en) | 2019-04-24 | 2021-10-26 | Theravance Biopharma R&D Ip, Llc | Ester and carbonate pyrimidine compounds as JAK kinase inhibitors |
| CA3135388A1 (en) | 2019-04-24 | 2020-10-29 | Theravance Biopharma R&D Ip, Llc | Pyrimidine jak inhibitors for the treatment of skin diseases |
-
2018
- 2018-10-26 GE GEAP201815340A patent/GEP20227344B/en unknown
- 2018-10-26 US US16/171,693 patent/US10308646B2/en active Active
- 2018-10-26 RS RS20220903A patent/RS63608B1/sr unknown
- 2018-10-26 WO PCT/US2018/057682 patent/WO2019084383A1/en unknown
- 2018-10-26 ES ES18801171T patent/ES2932526T3/es active Active
- 2018-10-26 SG SG11202001706RA patent/SG11202001706RA/en unknown
- 2018-10-26 MA MA49956A patent/MA49956B1/fr unknown
- 2018-10-26 CN CN201880068081.5A patent/CN111247142B/zh active Active
- 2018-10-26 MX MX2020004255A patent/MX2020004255A/es unknown
- 2018-10-26 PE PE2020000414A patent/PE20201495A1/es unknown
- 2018-10-26 CA CA3074034A patent/CA3074034A1/en active Pending
- 2018-10-26 AR ARP180103131A patent/AR113803A1/es unknown
- 2018-10-26 EP EP18801171.2A patent/EP3672965B1/en active Active
- 2018-10-26 IL IL274037A patent/IL274037B2/en unknown
- 2018-10-26 LT LTEPPCT/US2018/057682T patent/LT3672965T/lt unknown
- 2018-10-26 CR CR20200180A patent/CR20200180A/es unknown
- 2018-10-26 HU HUE18801171A patent/HUE060401T2/hu unknown
- 2018-10-26 TW TW107137865A patent/TWI789446B/zh active
- 2018-10-26 HR HRP20221221TT patent/HRP20221221T1/hr unknown
- 2018-10-26 EA EA202091016A patent/EA202091016A1/ru unknown
- 2018-10-26 JP JP2020523324A patent/JP7218364B2/ja active Active
- 2018-10-26 BR BR112020008015-2A patent/BR112020008015A2/pt unknown
- 2018-10-26 KR KR1020207012597A patent/KR102613503B1/ko active IP Right Grant
- 2018-10-26 SI SI201830770T patent/SI3672965T1/sl unknown
- 2018-10-26 CU CU2020000053A patent/CU24671B1/es unknown
- 2018-10-26 PT PT188011712T patent/PT3672965T/pt unknown
- 2018-10-26 AU AU2018354370A patent/AU2018354370B2/en active Active
- 2018-10-26 DK DK18801171.2T patent/DK3672965T3/da active
- 2018-10-26 UA UAA202003146A patent/UA125130C2/uk unknown
- 2018-10-26 PL PL18801171.2T patent/PL3672965T3/pl unknown
- 2018-10-26 MD MDE20200681T patent/MD3672965T2/ro unknown
-
2019
- 2019-04-22 US US16/390,175 patent/US10562894B2/en active Active
-
2020
- 2020-01-08 US US16/737,067 patent/US10774080B2/en active Active
- 2020-03-13 PH PH12020500528A patent/PH12020500528A1/en unknown
- 2020-03-16 ZA ZA2020/01641A patent/ZA202001641B/en unknown
- 2020-04-23 CL CL2020001090A patent/CL2020001090A1/es unknown
- 2020-04-24 NI NI202000032A patent/NI202000032A/es unknown
- 2020-04-27 EC ECSENADI202023795A patent/ECSP20023795A/es unknown
- 2020-05-06 DO DO2020000083A patent/DOP2020000083A/es unknown
- 2020-08-12 US US16/991,268 patent/US10988470B2/en active Active
-
2021
- 2021-03-30 US US17/301,243 patent/US11420965B2/en active Active
-
2022
- 2022-06-30 US US17/855,539 patent/US11814377B2/en active Active
-
2023
- 2023-10-03 US US18/480,442 patent/US20240158389A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2020000083A (es) | Compuesto de pirimidina como inhibidor de las janocinasas | |
| CO2018005640A2 (es) | Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria | |
| CO2019011809A2 (es) | Compuestos de imidazo-piperidina fusionada como inhibidores de jak | |
| CO2017012267A2 (es) | Compuestos de naftiridina como inhibidores de la quinasa jak | |
| CO2018011408A2 (es) | Compuestos de pirimidina como inhibidores de la quinasa jak | |
| BR112021007788A8 (pt) | Composto inibidor de jak 2-azabiciclo hexano | |
| CO2021002977A2 (es) | Dimetilaminoazetidinaminas como inhibidores de jak | |
| CO2020001469A2 (es) | Compuestos bicíclicos de pirazol y triazolo como inhibidores de las cinasas jak | |
| EA201791576A1 (ru) | Ингибитор jak | |
| CR20130560A (es) | Compuestos de bezotiazol y su uso farmacéutico | |
| CO6660497A2 (es) | Derivados del ácido nft-2-ilacético para tratar el sida | |
| MX2020004283A (es) | Derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6. | |
| PH12021550388A1 (en) | Process for preparing jak inhibitors and intermediates thereof | |
| EA201792021A1 (ru) | Ингибитор jak | |
| CO2021002976A2 (es) | Amidas heterocíclicas de 5 a 7 miembros como inhibidores de jak | |
| EA201791802A1 (ru) | СШИТЫЕ ДИГИДРО-4H-ПИРАЗОЛО[5,1-c][1,4]ОКСАЗИНИЛОВЫЕ СОЕДИНЕНИЯ И АНАЛОГИ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ЦНС | |
| EA201790016A1 (ru) | АНАЛОГ ПИРИДИНО[1,2-a]ПИРИМИДОНА, ПРИМЕНЯЕМЫЙ В КАЧЕСТВЕ ИНГИБИТОРА PI3K | |
| CO2020000371A2 (es) | Intermedios útiles para la síntesis de un inhibidor selectivo contra proteín cinasas y procesos para preparar los mismos | |
| CO2019008110A2 (es) | Activador de nrf2 | |
| CL2022002975A1 (es) | Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus métodos de uso | |
| CO2019001644A2 (es) | Derivado de triazolopirazinona útil como un inhibidor de pde1 humana |